Anti-A2AP antibodies and uses thereof

US12215168B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Stefan Heitmeier · Wülfrath, DE
• Julia Glunz · Essen, DE
• Melanie FISCHER · Riedstadt, DE
• Cindy SCHULENBURG · Leverkusen, DE
• Hannah Jörißen · Heiligenhaus, DE
• Christoph Thiel · Bad Mergentheim, DE
• Andreas Wilmen · Neunburg vorm Wald, DE
• Ernst Weber · Langenfeld, DE

Key dates

• Filing date: Nov 30, 2023
• Grant date: Feb 4, 2025
• Expiry date: Nov 30, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and/or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.